NBW Capital LLC Buys 4,152 Shares of Repligen Co. (NASDAQ:RGEN)

NBW Capital LLC grew its stake in Repligen Co. (NASDAQ:RGEN) by 19.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 25,194 shares of the biotechnology company’s stock after purchasing an additional 4,152 shares during the quarter. NBW Capital LLC’s holdings in Repligen were worth $3,626,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Creative Planning raised its stake in Repligen by 32.6% in the third quarter. Creative Planning now owns 5,123 shares of the biotechnology company’s stock worth $762,000 after buying an additional 1,259 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Repligen by 133.2% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 4,009 shares of the biotechnology company’s stock worth $597,000 after acquiring an additional 2,290 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in shares of Repligen by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,044 shares of the biotechnology company’s stock valued at $899,000 after purchasing an additional 410 shares during the period. QRG Capital Management Inc. boosted its position in shares of Repligen by 12.5% during the third quarter. QRG Capital Management Inc. now owns 3,642 shares of the biotechnology company’s stock valued at $542,000 after purchasing an additional 406 shares in the last quarter. Finally, Equitable Trust Co. grew its stake in Repligen by 52.8% in the third quarter. Equitable Trust Co. now owns 2,577 shares of the biotechnology company’s stock worth $384,000 after purchasing an additional 891 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the company. TD Cowen started coverage on Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price objective for the company. StockNews.com cut shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Friday, February 21st. Canaccord Genuity Group assumed coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price for the company. Finally, Royal Bank of Canada upped their price target on Repligen from $203.00 to $205.00 and gave the stock an “outperform” rating in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $181.00.

Repligen Stock Performance

Shares of RGEN opened at $155.38 on Tuesday. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $203.13. The business’s fifty day simple moving average is $156.37 and its two-hundred day simple moving average is $148.43. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The company has a market cap of $8.71 billion, a price-to-earnings ratio of -304.67, a P/E/G ratio of 4.54 and a beta of 0.99.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. Research analysts anticipate that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.